Impedimed Ltd (ASX: IPD) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Impedimed Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$182.08 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
2.02 billion
Earnings per share
-0.006
Dividend per share
N/A
Year To Date Return
-37.93%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Impedimed Ltd (ASX: IPD)
Latest News
⏸️ Investing
Why the shares of biotech star Impedimed Limited are rocketing today
⏸️ Investing
3 explosive healthcare shares to give your portfolio a boost
⏸️ Investing
Beat the market with these 3 growing healthcare shares
⏸️ Investing
Here's why these 4 ASX shares are storming higher today
⏸️ Investing
Here's why the shares of biotech Impedimed Limited are soaring today
⏸️ Investing
Why these 4 ASX shares are soaring today
⏸️ Investing
Does biotech Impedimed Limited have blockbuster potential?
⏸️ Investing
Here's why these 4 shares crashed on the market today
⏸️ Investing
Watch the Fed: rising US rates will support these Australian blue chips
⏸️ Investing
Is this company the next Nanosonics Ltd. or Impedimed Limited?
⏸️ Investing
10 S&P/ASX 300 stocks every investor needs on their watchlist
⏸️ Investing
Two small cap stocks I am banking on in 2015
Frequently Asked Questions
-
No, Impedimed does not pay shareholder dividends at this time.
-
Impedimed Limited listed on the ASX on 24 October 2007.
IPD ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Impedimed Ltd
Impedimed Ltd (ASX: IPD) is a global leader in the design and manufacture of medical devices that use bioimpedance spectroscopy (BIS) technologies in the non-invasive clinical assessment of fluid and tissue composition.
The company's products are typically used to assess and monitor lymphedema and heart failure, as well as to measure patients' tissue composition and fluid status. They also have general health applications in weight management, nutritional issues, and assessing bone content.
As well, Impedimed offers a cloud-based digital platform to manage patient data. The company is based in Australia and generates most of its revenue in North America.
IPD Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 24 Apr 2024 | $0.09 | $0.00 | 0.00% | 900,191 | $0.09 | $0.09 | $0.09 |
| 23 Apr 2024 | $0.09 | $0.00 | 0.00% | 639,897 | $0.09 | $0.09 | $0.09 |
| 22 Apr 2024 | $0.09 | $0.00 | 0.00% | 808,812 | $0.09 | $0.09 | $0.09 |
| 19 Apr 2024 | $0.09 | $0.00 | 0.00% | 1,210,425 | $0.10 | $0.10 | $0.09 |
| 18 Apr 2024 | $0.10 | $0.00 | 0.00% | 1,334,047 | $0.10 | $0.11 | $0.10 |
| 17 Apr 2024 | $0.09 | $0.00 | 0.00% | 4,733,796 | $0.09 | $0.11 | $0.09 |
| 16 Apr 2024 | $0.09 | $0.01 | 11.24% | 2,455,687 | $0.09 | $0.10 | $0.09 |
| 15 Apr 2024 | $0.09 | $0.00 | 0.00% | 473,132 | $0.09 | $0.09 | $0.09 |
| 12 Apr 2024 | $0.09 | $0.00 | 0.00% | 289,598 | $0.09 | $0.09 | $0.09 |
| 11 Apr 2024 | $0.09 | $-0.01 | -10.20% | 765,169 | $0.10 | $0.10 | $0.09 |
| 10 Apr 2024 | $0.10 | $0.01 | 11.11% | 1,850,719 | $0.09 | $0.10 | $0.09 |
| 09 Apr 2024 | $0.09 | $0.00 | 0.00% | 589,448 | $0.09 | $0.09 | $0.09 |
| 08 Apr 2024 | $0.09 | $0.00 | 0.00% | 980,061 | $0.09 | $0.09 | $0.09 |
| 05 Apr 2024 | $0.09 | $0.00 | 0.00% | 613,279 | $0.09 | $0.10 | $0.09 |
| 04 Apr 2024 | $0.09 | $0.01 | 11.49% | 940,984 | $0.09 | $0.09 | $0.09 |
| 03 Apr 2024 | $0.09 | $0.00 | 0.00% | 424,201 | $0.09 | $0.09 | $0.09 |
| 02 Apr 2024 | $0.09 | $-0.01 | -10.87% | 1,216,371 | $0.09 | $0.09 | $0.09 |
| 28 Mar 2024 | $0.09 | $0.01 | 11.63% | 1,158,154 | $0.09 | $0.09 | $0.09 |
| 27 Mar 2024 | $0.09 | $0.00 | 0.00% | 784,145 | $0.09 | $0.09 | $0.09 |
| 26 Mar 2024 | $0.09 | $0.00 | 0.00% | 1,049,915 | $0.09 | $0.09 | $0.09 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 25 Mar 2024 | Janelle Delaney | Buy | 568,181 | $49,999 |
On-market trade.
|
| 22 Mar 2024 | Janelle Delaney | Buy | 581,395 | $49,999 |
On-market trade.
|
| 04 Mar 2024 | Janelle Delaney | Buy | 1,137,634 | $99,591 |
On-market trade.
|
| 29 Feb 2024 | Andrew Grant | Buy | 100,000 | $87,000 |
On-market trade.
|
| 28 Feb 2024 | Andrew Grant | Buy | 130,000 | $10,920 |
On-market trade.
|
| 28 Feb 2024 | Christine Emmanuel-Donnelly | Buy | 121,952 | $10,169 |
On-market trade.
|
| 14 Dec 2023 | Janelle Delaney | Buy | 942,232 | $135,148 |
On-market trade.
|
| 13 Dec 2023 | Christine Emmanuel-Donnelly | Buy | 67,857 | $9,499 |
On-market trade.
|
| 05 Dec 2023 | Janelle Delaney | Buy | 66,503 | $8,977 |
On-market trade.
|
| 04 Dec 2023 | Andrew Grant | Buy | 70,000 | $9,625 |
On-market trade.
|
| 20 Nov 2023 | Richard Valencia | Expiry | 20,000,000 | $2,600,000 |
As advised by the company. Lapse of Options and Performance Rights
|
| 20 Nov 2023 | Richard Valencia | Expiry | 10,000,000 | $1,300,000 |
Options expired.
|
| 01 Nov 2023 | Christine Emmanuel-Donnelly | Buy | 100,000 | $10,500 |
On-market trade.
|
| 03 Jul 2023 | David Anderson | Issued | 81,325 | $13,499 |
Director remuneration.
|
| 03 Jul 2023 | Amit Patel | Issued | 111,145 | $18,450 |
Director remuneration.
|
| 03 Jul 2023 | Donald (Don) Williams | Issued | 178,916 | $29,700 |
Director remuneration.
|
| 03 Jul 2023 | Janet West | Issued | 130,152 | $21,605 |
Director remuneration.
|
| 20 Jun 2023 | David Anderson | Buy | 920,000 | $143,980 |
On-market trade.
|
| 13 Jun 2023 | Donald (Don) Williams | Buy | 1,000,000 | $157,500 |
On-market trade.
|
| 13 Jun 2023 | Janet West | Buy | 300,000 | $46,500 |
On-market trade.
|
| 06 Jun 2023 | Donald (Don) Williams | Transfer | 130,000 | $20,150 |
Off-market transfer.
|
| 06 Jun 2023 | Donald (Don) Williams | Transfer | 130,000 | $20,150 |
Off-market transfer.
|
| 06 Jun 2023 | Donald (Don) Williams | Buy | 500,000 | $82,300 |
On-market trade.
|
| 27 Apr 2023 | Donald (Don) Williams | Buy | 100,000 | $17,500 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr Parmjot Bains | Managing DirectorInterim CEO | Jan 2024 |
Dr Bains is a healthcare executive with experience including strategy, sales & marketing, commercial execution, and change management across the US, Asia, Middle East and Australia. Dr Bains joined Pfizer US in 2015 and since then has held several roles located in the United States, Asia Pacific and Middle East. Most recently, Dr Bains was Pfizers Gulf Cluster Country Manager, responsible for setting commercial strategy, aligning team capabilities, driving private and public reimbursement, accelerating sales & marketing activities and key account management. Dr Bains managed a large team across six countries and six therapeutic areas (including breast cancer). Dr Bains former roles include: joint CEO and Chief Operating Officer at Neuren Pharmaceuticals (ASX: NEU) (developing therapies for brain injury, neurodevelopmental and neurodegenerative disorder); CEO of Perseis Therapeutics, (creating monoclonal antibody candidates against breast cancer targets); manager at McKinsey and Company and medical doctor.
|
| Mr Andrew John Grant | Non-Executive Director | Sep 2023 |
--
|
| Mr McGregor Grant | Executive ChairmanExecutive DirectorInterim CFO | Nov 2023 |
--
|
| Ms Christine Emmanuel-Donnelly | Non-Executive Director | Sep 2023 |
--
|
| Ms Janelle Delaney | Non-Executive Director | Sep 2023 |
--
|
| Ms Leanne Ralph | Company Secretary | Jan 2015 |
-
|
| Timothy Cruickshank | Chief Financial Officer |
-
|
|
| Shashi Tripathi | Chief Operating Officer |
-
|
|
| Joann Yao | Chief Strategy Officer |
-
|
|
| Leanne Ralph | Company Secretary |
-
|
|
| Dennis Schlaht | Senior Vice President R&D and Technology |
-
|
|
| Lisa Prom | Vice President Sales |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| National Nominees Limited | 190,580,959 | 9.44% |
| Citicorp Nominees Pty Limited | 176,271,813 | 8.73% |
| J P Morgan Nominees Australia Pty Limited | 122,801,902 | 6.08% |
| HSBC Custody Nominees (Australia) Limited | 86,660,527 | 4.29% |
| Bnp Paribas Noms Pty Ltd | 71,262,491 | 3.53% |
| BNP Paribas Nominees Pty Ltd | 56,357,329 | 2.79% |
| HSBC Custody Nominees (Australia) Limited i | 47,593,537 | 2.36% |
| HSBC Custody Nominees (Australia) Limited A/C 2 | 28,525,714 | 1.42% |
| Moore Family Nominee Pty Ltd | 22,500,000 | 1.11% |
| Mba Investments Pty Ltd | 22,490,990 | 1.11% |
| Mr Hamish Alexander Jones | 21,263,705 | 1.05% |
| Mr Gregory Wayne Brown | 21,100,000 | 1.05% |
| Sunlora Pty Ltd | 19,000,000 | 0.94% |
| Apex Investment Management Pty Limited | 17,471,778 | 0.87% |
| BNP Paribas Nominees Pty Ltd i | 16,201,010 | 0.82% |
| Pakasoluto Pty Limited | 16,011,422 | 0.79% |
| Mr Stephen Edward Mahnken & Mrs Dior Leone Mahnken | 16,000,000 | 0.79% |
| Dr Hsien Michael Soo | 15,394,710 | 0.76% |
| Bsd Pty Ltd | 13,300,000 | 0.66% |
| Mid Dig Investments Pty Ltd | 12,970,633 | 0.64% |
